Palisade Bio, Inc. (PALI)
$1.47-7.55%Close
SELLCRISIS · day 20
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $255M
- Beta
- 1.62
- P/E (TTM)
- -2.76
- Short % float
- 18.58%
- Days to cover
- 6.1
- SI change
- +2.5%
- 1W
- -1.34%
- 1M
- -28.29%
- vs SPY 1W
- -1.20%
- vs SPY 1M
- -30.80%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on PALI?
- LOPJLB’s latest quantitative signal on Palisade Bio, Inc. (PALI) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is PALI in?
- Palisade Bio, Inc. (PALI) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Palisade Bio, Inc. (PALI) do?
- Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibros…